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Abstract: Duchenne muscular dystrophy (DMD) is a lethal X-linked recessive disorder caused by
mutations in the DMD gene and the subsequent lack of dystrophin protein. Recently, phosphorodi-
amidate morpholino oligomer (PMO)-antisense oligonucleotides (ASOs) targeting exon 51 or 53 to
reestablish the DMD reading frame have received regulatory approval as commercially available
drugs. However, their applicability and efficacy remain limited to particular patients. Large animal
models and exon skipping evaluation are essential to facilitate ASO development together with a
deeper understanding of dystrophinopathies. Using recombinant adeno-associated virus-mediated
gene targeting and somatic cell nuclear transfer, we generated a Yucatan miniature pig model of
DMD with an exon 52 deletion mutation equivalent to one of the most common mutations seen
in patients. Exon 52-deleted mRNA expression and dystrophin deficiency were confirmed in the
skeletal and cardiac muscles of DMD pigs. Accordingly, dystrophin-associated proteins failed to be
recruited to the sarcolemma. The DMD pigs manifested early disease onset with severe bodywide
skeletal muscle degeneration and with poor growth accompanied by a physical abnormality, but
with no obvious cardiac phenotype. We also demonstrated that in primary DMD pig skeletal muscle
cells, the genetically engineered exon-52 deleted pig DMD gene enables the evaluation of exon 51 or
53 skipping with PMO and its advanced technology, peptide-conjugated PMO. The results show that
the DMD pigs developed here can be an appropriate large animal model for evaluating in vivo exon
skipping efficacy.
Int. J. Mol. Sci. 2021, 22, 13065. https://doi.org/10.3390/ijms222313065 https://www.mdpi.com/journal/ijms
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1. Introduction
Duchenne muscular dystrophy (DMD) is an X chromosome-linked recessive neu-
romuscular disorder caused by mutations in the DMD gene and the subsequent lack of
dystrophin protein [1]. The incidence has been reported to be in the range of 10.7 to
27.8 cases per 100,000 live male births [2]. One of the most common mutation types is
a deletion of entire exon(s) in the DMD gene, accounting for approximately 68% of the
patients’ mutations [3]. The mutations lead to the DMD reading frame disruption referred
to as out-of-frame and generate premature stop codons. Dystrophinopathy is characterized
by progressive weakness and degeneration in bodywide skeletal muscles [4]. Patients are
initially recognized due to their abnormal gait and lose ambulation by 10–13 years [5],
accompanied by high serum creatine kinase levels [6]. With improved respiratory support,
cardiac involvement is currently a leading cause of premature death in the 20 s to 40 s in
affected individuals [7,8].
Dystrophic animal models have promoted understanding of DMD pathology, lead-
ing to the development of various candidate therapies aimed at restoring the expression
of dystrophin protein or correcting physiological pathways involved in the pathogene-
sis [9,10]. Of these, currently, a most promising therapeutic approach is exon skipping
using short, synthetic antisense oligonucleotides (ASOs) to restore the reading frame of
DMD mRNA, thus generating, functional though truncated, dystrophin protein. In the
past five years, four phosphorodiamidate morpholino oligomers (PMOs) have been condi-
tionally approved by the U.S. Food and Drug Administration (FDA), including eteplirsen
for exon 51 skipping [11], golodirsen [12], and viltolarsen [13] for exon 53 skipping, and
casimersen for exon 45 skipping [14]. Encouragingly, an applied technology has already
emerged using cell-penetrating peptide (CPP) conjugations to PMOs, enabling PMOs to be
taken more efficiently into skeletal and cardiac muscle cells and to skip exon(s) of a target
transcript [15,16].
Dystrophic mice and dogs have played significant roles in demonstrating the proof-of-
concept of ASO-mediated exon skipping [17–21]; however, the murine and canine models
have some limitations regarding their physical and genetic resemblance to patients [22].
First, the mdx mouse has a milder phenotype, raising a question as to whether findings will
translate to patients. Second, their mutations, such as the point mutation in exon 23 in mdx
mice are not commonly seen in DMD patients. Lastly, murine and canine anatomy and
physiology are distant from humans, limiting interpretation and extrapolation of treatment
effects from animal to human. Although the wide variety of currently available animal
models may partially compensate for these drawbacks [23], a more suitable animal model,
particularly a large animal model, is most desirable to overcome them.
As such a model, pigs, particularly miniature pigs, are scientifically accessible and
socially more acceptable than canine models. In many respects, the pig is more similar to
the human than most other models, potentially helping to fill the substantial gap between
currently available animal models and patients. Also, they are more amenable to the
cloning technology of somatic cell nuclear transfer (SCNT) to obtain genetically identical
piglets, as we previously demonstrated [24]. In contrast, SCNT in dogs has been reported to
suffer from poor efficiency [25]. This unique property enables the production of various pig
models of human diseases combined with genetic engineering technologies such as gene
targeting [26]. These advantages provide an opportunity to introduce deletion mutations
in “hotspot” regions as seen in patients [27], increasing the applicability of transgenic
pigs to preclinical testing. Encouragingly, the development of such cloned pigs with the
genetically engineered mutant DMD gene has been progressing [28–31]. However, further
Int. J. Mol. Sci. 2021, 22, 13065 3 of 21
development and characterization of DMD pig models are essential to reveal the value of
their applicability to preclinical research and better understand their pathogenesis.
In this study, we used a combination method of recombinant adeno-associated virus
(rAAV)-mediated gene targeting and SCNT to generate a tailored DMD mutant pig [24].
Consequently, we developed a Yucatan miniature pig model of DMD with an exon 52
deletion mutation that mimics one of the most common mutations in patients [27]. These
resultant DMD exon 52-deleted pigs (DMDex52del pigs) were molecularly and histologically
characterized. Also, through in vitro tests with the primary DMDex52del pig skeletal muscle
cells, the present study reports the potential of DMDex52del pigs for the development of
CPP-conjugated PMO-mediated exon skipping.
2. Results
2.1. Generation of a Miniature Pig Model of Duchenne Muscular Dystrophy
A Yucatan miniature pig model of DMD was generated by homologous recombination
via rAAV–mediated gene targeting that creates an exon 52 deletion in the pig DMD gene
and SCNT (Figure. 1A) [24]. Male pig fetal fibroblasts were infected with rAAV carrying a
targeting construct designed to replace the endogenous DMD exon 52 with a neomycin
resistance cassette (NeoR) driven by the phosphoglycerate kinase (PGK) promoter, flanked
by loxP sites (Figure 1B).
Figure 1. Cont.
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Figure 1. Overview of generation of the clonal miniature pigs with a DMD exon-52 deletion mutation.
(A) Schematic of the combination method of the rAAV-mediated gene targeting and somatic cell
nuclear transfer for producing the cloned DMD-targeted male piglets. Fibroblast cells derived from
male pigs at the age of 35-days were obtained and infected with the rAAV packaging DMDex52del
targeted vector identified by a red asterisk. The DMD-targeted male pig fibroblast nucleus was
transferred into enucleated oocytes, followed by fusion and activation in cells. The nuclear transfer
(NT) embryos were transferred into the uterus of a recipient pig. After a 114 day gestation period,
DMD-targeted piglets were produced. (B) Porcine DMD exon 52 was replaced with a neomycin
resistance cassette (NeoR) (orange) driven by a phosphoglycerate kinase (PGK) promoter (yellow)
and flanked by loxP sites (blue). Exons 51–53 of porcine DMD are depicted in black boxes. The rAAV
inverted terminal repeats (ITRs) are in red. Each homology arm is ~1.4 kb in length. The figure is not
to scale.
The resulting DMD exon 52-deleted fibroblasts were used as nuclear donors for SCNT.
We performed the SCNT with genetically engineered male fibroblasts, generating a total
of seven affected males (Tabe S1). The genotype of each pig produced was confirmed
by PCR using primers (Table S2) and Southern blotting using probes that hybridize the
DMD region or NeoR sequence (Figure 2A,B, respectively). Of these seven piglets, five died
within a week, and two survived up to 6.5 and 7 months of age, respectively. Expression
of exon 52-deleted mRNA in skeletal and cardiac muscles was shown by RT-PCR and the
boundary of exons 51 and 53 was confirmed by direct sequencing (Figure 2C), validating
the out-of-frame mRNA in the affected pigs. Dystrophin was absent in skeletal and cardiac
muscles as shown by Western blotting with antibodies against the dystrophin rod and
C-terminal domains (Figure 2D). Western blotting also revealed reduced expression levels
of dystrophin-associated proteins (DAPs), neuronal nitric oxide synthase (nNOS) and
α-sarcoglycan.
Figure 2. Cont.
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Figure 2. Molecular characterization of the DMD exon 52-deleted miniature pig model. (A) Genotyp-
ing PCR using umbilical cord tissue lysates confirmed the exon 52 deletion in the pig DMD gene.
Lanes 1–5 represent PCR amplicons of the DMD region of DMDex52del pigs. Lane 6 is a lysate from a
wild-type pig. (B) Representative genomic Southern blot of 3 DMDex52del pigs. (Left) MfeI-digested
genomic DNA was hybridized with a probe that detects porcine DMD downstream of the target-
ing vector boundary. The DMD-targeted allele produced an approximately 6.3 kb band, and the
wild-type band is 4.7 kb. (Right) The same DNA was hybridized with a probe that detects the NeoR,
yielding only the targeted 6.3 kb band. Lane 1: wild-type; Lanes 2–4: individual DMDex52del male
pigs. (C) RT-PCR revealed exon 52-deletion in DMD mRNA in the skeletal and cardiac muscles.
TA, tibialis anterior; GAS, gastrocnemius; DIA, diaphragm; LV, left ventricular free wall; RV, right
ventricular free wall. (D) Lack of dystrophin and reduction in its associated protein levels in skeletal
and cardiac muscles as represented by Western blotting. Dystrophin (Dys) rod domain and Dys
C-terminal were detected by monoclonal antibodies, NCL-DYS1 and NCL-DYS2, respectively. nNOS,
Neuronal nitric oxide synthase. MyHC, myosin heavy chain stained by Coomassie Brilliant Blue in a
post-transferred gel.
2.2. Dystrophin Deficiency Causes Failed Recruitment of DAPs to the Sarcolemma of the
Transgenic Pig Model
Immunohistochemistry with serial frozen sections of skeletal muscles of the DMDex52del
pig model revealed the lack of dystrophin in the muscle membrane, accompanied by
reduced expression of DAPs (Figure 3). The DAPs such as α-syntrophin, nNOS, α-
sarcoglycan, and β-dystroglycan were not recruited to the muscle membrane. The signal
intensity of sarcolemmal utrophin, a homolog of dystrophin, was slightly increased in the
affected pig skeletal muscles compared to wild-type pigs, as seen in patients [32] and other
murine [33] and canine [34] models.
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On phenotypic assessment, we observed progressive muscle weakness in DMDex52del 
pigs (IDs 9286 and 9291) with age (Figure 5A), essentially identical to dog models of DMD 
[19,22,36]. The DMDex52del pigs demonstrated less activity and dystrophic phenotypes such 
as an enlarged tongue (macroglossia), postural instability, and associated forward posi-
tioning of the pelvic limbs as seen in another large animal model, the GRMD dog [36]. 














Figure 3. Reduction in dystrophin and dystrophin- ociated proteins in serial sections of DMDex52del pig skeletal muscles.
Dystrophin localization was analyzed using antibodies against the rod domain (ab85302, Abcam) or C-terminal (ab15277,
Abcam). Other antibodies used here are shown in Table S3. Repre entative im ges n the quadrice s and diaphragm
muscles of the dystrophic pig (ID 9290) at the age of 5 days are shown. Bar, 100 µm.
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2.3. Severe Pathology in DMDex52del Pig Muscles
The absence of dystrophin expression was confirmed in the DMDex52del pig model’s
skeletal and cardiac muscles using immunohistochemistry (Figure 4A). Dystrophin-positive
revertant fibres were sporadically observed as single fibres on the dystrophin-negative
muscle background, as shown in Figure 4A. A cluster as seen in mouse models was not
found through observation [35]. Accompanying the lack of dystrophin protein, severe
degeneration was seen in skeletal muscles in the DMD piglets from 5 days of age with
haematoxylin and eosin (H&E) staining and Masson’s trichrome staining (Figure 4B,C).
Centrally nucleated fibres were observed in the skeletal muscles in H&E staining. Necrotic
fibres and fibrosis were confirmed in the skeletal muscles of the tibialis anterior muscle,
gastrocnemius muscle, and diaphragm muscle on Masson’s trichrome staining. Unlike
the skeletal muscles, the left and right ventricles of the heart did not show noticeable
histological changes.
Figure 4. Muscle degeneration in the dystrophin-deficient DMDex52del pigs. (A) Dystrophin deficiency
in skeletal and cardiac muscles was confirmed by immunohistochemistry with anti-dystrophin rod
domain antibody (NCL-DYS1). An asterisk identifies a dystrophin positive-revertant fibre. Muscle
degeneration was assessed in (B) H&E staining and (C) Masson’s trichrome staining. Blue indicates
collagenous connective tissues. Representative images of an affected male piglet (ID 9290) at the age
of 5 days are shown.
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2.4. DMDex52del Pigs Exhibit Muscle Weakness and Poor Growth Rate
On phenotypic assessment, we observed progressive muscle weakness in DMDex52del
pigs (IDs 9286 and 9291) with age (Figure 5A), essentially identical to dog models of
DMD [19,22,36]. The DMDex52del pigs demonstrated less activity and dystrophic phe-
notypes such as an enlarged tongue (macroglossia), postural instability, and associated
forward positioning of the pelvic limbs as seen in another large animal model, the GRMD
dog [36]. Serum creatinine kinase was severely elevated to an average 19,581 U/L, stan-
dard error of the mean (SEM) ± 2021 (to convert U/L to µkat/L, multiply by 0.0167) in
DMDex52del pigs within 24 h after birth compared to that in wild-type pigs (an average
816 U/L, SEM ± 267) (Figure 5B), consistent with what is seen in newborn patients and
other animal models [6,37]. Growth of dystrophic pigs was remarkably impaired from
2 months of age compared to age-matched wild-type miniature pigs (Figure 5C). The
affected pigs were euthanized around seven months of age due to their diminished body
condition and weight loss.
Figure 5. DMDex52del pigs display dystrophic phenotypes in clinical assessment. (A) Physical abnormality in male
DMDex52del pigs at 15 weeks of age (IDs 9286 and 9291) with postural instability and associated forward positioning
of the pelvic limbs. (B) Serum creatine kinase measurements from wild-type (n = 3) and DMD pigs (n = 4) on the day of
birth. Error bars indicate SEM. (C) The poor growth rate of DMD pigs compared to age-matched wild-type (WT) pigs.
2.5. Design of Pig Antisense Oligonucleotide Sequences and Prediction of Exon Skipping Efficiency
For testing exon skipping feasibility in the mutant pig DMD gene, we first computa-
tionally designed a total of 204 and 183 30-mer ASO sequences for use with PMO chemistry,
to skip pig DMD exons 51 and 53, respectively (Tables S4 and S5). Pig ASOs were designed
based on a prediction of exon-skipping efficiency for each possible target site across the
entire sequence of each target exon. The prediction was facilitated by a computational tool
we previously developed to design ASOs to skip human DMD exons [38]. The in silico
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prediction revealed that the upstream region of both pig DMD exons 51 and 53 could be
optimal for skipping efficacy (Figure S1A,B). The effective and ineffective regions computa-
tionally calculated for the pig DMD exons were similar to those for humans (Figure S1C,D),
suggesting the potential utility of our algorithms to design effective ASO sequences for
the animal gene. For empirical tests, we selected five ASOs for each exon based on the
ranking with the predicted skipping efficiency values and on referring to the previous
achievement of the test in the patient DMD gene (Table 1). Namely, for ASOs tested to
skip exon 51, pEx51_Ac0 and pEx51_Ac48 were the analogues of the ASOs that were the
most and second-most effective, respectively, at skipping human DMD exon 51 in vitro and
in vivo [39]. pEx51_Ac5 had the highest predicted value (89.1%) in the present calculation.
pEteplirsen_Ac65 and pDrisapersen_Ac67 were the pig version PMO sequences of the
FDA-approved PMO, eteplirsen [40] and clinically trialed 20-mer 2′-O-methyl phospho-
rothioate oligonucleotide, drisapersen, respectively [41]. Pig DMD exon 53 skipping ASOs
were selected from among the target sites having the top thirty of the predicted skipping
values. Of them, pEx53_Ac26, which had the tenth-highest ranking for pig target sites,
was the analogue sequence of the human site that had the greatest efficiency at skipping
exon 53 in the DMD patient-derived skeletal muscle cells [38]. pEx53_Ac9 was a 30-mer
sequence with the top-ranked skipping value in the prediction of 88.8%. All ASOs were
synthesized as PMOs (Gene Tools).
Table 1. Pig morpholino sequences and their predicted efficiency of skipping pig exon 51 or 53.





pEx51_Ac0 GTGTCACCAGAGTAACAGTCTGACTAGTAG 51 30 79.7 6 0
pEx51_Ac5 GGGTTGTGTCACCAGAGTAACAGTCTGACT 51 30 89.1 1 5
pEx51_Ac48 ATGGCATTTCTGGTTTGGAGATGGCAGTTT 51 30 37.1 80 48
pEte_Ac65 CTCCAACAGCAAGGAAGATGGCATTTCTGG 51 30 55.4 34 65
pDri_Ac67 GCAAGGAAGATGGCATTTCT 51 20 NA NA 67
pEx53_Ac9 GTTCCTGGACCTCATCCCACTGACTCTGTA 53 30 88.8 1 9
pEx53_Ac17 CTGAAGGTGTTCCTGGACCTCATCCCACTG 53 30 77.8 7 17
pEx53_Ac18 TCTGAAGGTGTTCCTGGACCTCATCCCACT 53 30 70.0 16 18
pEx53_Ac26 CCTTCTGTTCTGAAGGTGTTCCTGGACCTC 53 30 75.6 10 26
pEx53_Ac30 GTTGCCTTCTGTTCTGAAGGTGTTCCTGGA 53 30 53.4 30 30
Underlines indicate the different bases between pigs and humans. pEte, pig version of eteplirsen; pDri, pig version of drisapersen; NA, not
available; Ac, acceptor splice site.
2.6. PMO-Mediated Exon Skipping Is Feasible in DMDex52del Pig Skeletal Muscle Cells In Vitro
To evaluate exon skipping PMO potency in pig muscle cells, we generated primary
skeletal muscle cells from wild-type and DMDex52del miniature pigs (IDs 9594 and 9595).
The maturation of the differentiated pig skeletal muscle cells appropriate for testing exon
skipping was confirmed by the expression of DMD mRNA produced at the late stage of
myotube formation during myogenesis (Figure 6) [39].
PMOs (10 µM) were transfected to the myotubes differentiated from the primary
DMD pig skeletal muscle cells at the fourth or fifth passage (Figure S2A). All PMOs tested
succeeded in skipping exon 51 or 53 in the DMD pig skeletal muscle cells as represented
by RT-PCR (Figures 6 and S3). In the in vitro test of exon 51 skipping, pEx51_Ac48 PMO
showed the greatest efficiency, reaching up to 64%, followed by pEteplirsen_Ac65 PMO
(Figures 6A and S3A). Interestingly, 20-mer pDrisapersen_Ac67 PMO at 10 µM induced
up to 40% exon skipping efficiency in the DMD pig muscle cells, whereas 10 µM human
PMO composed of drisapersen sequence had been reported to have no practical ability
to skip exon 51 in a DMD patient muscle cell line with the same exon 52 deletion mu-
tation using the identical method to the present study [39]. The boundary composed of
exons 50 and 53 in the exon 51-skipped transcripts was confirmed by direct sequencing,
indicating the induction of in-frame mRNA following the treatment of exon 51 skipping
PMOs. Accordingly, the rescued dystrophin protein was observed on Western blotting in
the DMD pig cells treated with PMOs, with a particularly strong signal for pEx51_Ac48
PMO (Figure 6B). Five PMOs for exon 53 skipping also successfully induced in-frame tran-
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scripts at the exon 51-54 junction in primary skeletal muscle cells following the treatment
(Figures 6C and S3B). The highest efficiency for exon 53 skipping was 37% for pEx53_Ac26
PMO. Dystrophin rescue was not detected by Western blotting in pig cells treated with exon
53 skipping PMOs due to their lower exon skipping efficiencies, consistent with exon 51
skipping result using pEx51_Ac5 or pDrisapersen PMOs that showed no apparent rescued
protein bands.
Figure 6. The feasibility of DMD exon 51 or 53 skipping in the DMDex52del pig skeletal muscle cells
in vitro. Exon 51 skipping efficiency (A) and expression levels of rescued dystrophin protein (B) were
analyzed in primary DMD pig muscle cells treated with 10 µM PMOs and 6 µM transfection agent,
Endo-Porter (the culture condition is shown in Figure S2A). The efficiency of exon 53 skipping using
pig PMOs was also tested in primary DMD pig cells (C), but no dystrophin was detected on Western
blotting (D). pEte, the pig version PMO of FDA-approved eteplirsen; pDri, the pig version PMO of
drisapersen previously tested in a clinical trial as 2′-O-methyl phosphorothioate oligonucleotides.
WT, wild-type; NT, non-treated; Mock, 31-mer negative control PMO. Alpha-tubulin and MyHC
were used as a loading control and marker of myogenic differentiation, respectively. Representative
results from three independent experiments using two DMD pig cell lines derived from pigs with
IDs 9594 and 9595 are shown.
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2.7. Peptide Conjugation to PMOs Potentiates Exon Skipping Efficiency in DMDex52del Pig
Skeletal Muscle Cells
Cell-penetrating peptide, CPP, conjugation to PMOs is reported to increase efficacy at
skipping target exons and overcome PMO chemistry limitations such as relatively poor
delivery to muscle cells [42,43]. To examine if the pig model developed here is amenable
to such a CPP technology, we tested the in vitro efficacy of a CPP-, P7-conjugated PMOs
(P7-PMOs: Figure S2C) [44] with pEx51_Ac48 and pEx53_Ac26 sequences, confirming
these PMOs were more effective at skipping target exons, in primary DMDex52del pig cells.
Primary DMDex52del pig skeletal muscle cells were transfected with P7-conjugated PMOs
or unmodified PMO with or without a peptide-based transfection reagent, Endo-Porter
(Gene Tools) in the range of 125 nM to 5 µM, according to the culture schedule as shown in
Figure S2C.
On RT-PCR, whereas unmodified PMO tested at the highest concentration of 5 µM
without Endo-Porter induced up to 34% exon 51 skipping efficiency, similar effectiveness
was achieved with P7-PMO at the lower quantity of 250 nM (Figure 7A). The highest
efficiency for exon 51 skipping was 88% for 5 µM P7-PMO. Consistent with the exon 51
skipping result, exon 53 skipping P7-PMO tested at the lowest concentration (125 nM)
showed up to 13% efficiency (Figure 7B). Such a level was found with unmodified PMO
at the highest concentration of 5 µM. In P7-PMO-mediated exon 53 skipping, the highest
concentration (5 µM) induced up to 66% skipping efficiency. Together, P7-PMOs were
approximately 20- and 40-times more efficient in exon 51 and 53 skipping, respectively, than
unmodified PMOs concentration-wise, when tested in primary DMDex52del pig skeletal
muscle cells. Interestingly, in both exon 51 and 53 skipping, we found that the Endo-
Porter peptide reagent, unlike P7-conjugation, did not potentiate in vitro skipping ability
of unmodified PMO at 5 µM. Direct sequencing confirmed the junction of exons 50 and 53
or exons 51 and 54 of the exon-skipped transcripts.
Figure 7. A cell-penetrating peptide (P7)-conjugation potentiates the in vitro efficacy of morpholinos
(PMOs) at skipping exon 51 or 53 in the primary DMDex52del pig muscle cells as represented by
RT-PCR. (A) Exon 51 skipping efficiency comparison between unmodified PMO with or without a
transfection agent, Endo-Porter (EP) at 6 µM, and P7-peptide-conjugated PMO that have the Ac48
sequence. (B) Exon 53 skipping induced by Ac26-PMO with or without EP or with P7-conjugation.
M, 100 bp marker; NT, non-treated.
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3. Discussion
With preclinical studies using rodent and canine models, numerous efforts have been
made to develop therapeutic approaches for DMD such as small molecules, stop codon
readthrough, gene replacement, and exon skipping [10]. Dystrophic mouse models, notably
a series of mdx models, are valuable tools in the proof-of-concept stages of drug candidates
because the strains have been established and well characterized. Novel dystrophic models
with mice and rats are also further along in development utilizing their facility for genetic
manipulation [45–47]. On the other hand, canine models of GRMD and CXMDJ have
played pivotal roles in DMD research, as they display many of the clinical manifestations
seen in patients. While very useful, their limitations in physical similarity, severity, or
mutations have hampered moving the therapeutic approaches to the clinic.
Given a need for an appropriate model system to facilitate the discovery of drugs, in
the present study, using SCNT following rAAV-mediated gene targeting, we developed
a DMD exon 52-deleted miniature pig model that shows a lack of dystrophin protein
bodywide and a severe phenotype. As we previously reported [48], the cloning technology
of SCNT is an effective method for generating transgenic piglets compared to other methods
with porcine embryonic stem cells and induced pluripotent stem cells, which have some
limitations such as cell isolation difficulty, incomplete reprogramming, and a lower rate
of embryonic development in pigs [49–51]. The present study indicates that the SCNT
combined with gene targeting by the rAAV vector used here can facilitate generation
of DMD models with pigs harbouring genetic mutations of interest, together with other
genetic engineering technologies such as genome editing [28,29,52,53].
The molecular and histological evaluation in our study confirmed that our clonal
DMD miniature pigs with the exon 52 deletion, DMDex52del pigs, have severe phenotypes
with bodywide skeletal muscle degeneration. The model also manifested no dystrophin
protein expression in skeletal muscle, high serum creatine kinase levels, and progressive
disease status as seen in poor growth rate. Disrupted DAP assembly and revertant fi-
bre expression further demonstrate that the DMDex52del pig muscles manifest dystrophic
pathology features, as observed in the established murine and canine models [52,54]. The
increased levels of utrophin in the sarcolemma indicate that the DMDex52del pigs may have
a similar compensatory mechanism for the dystrophin deficiency to that found in other
animal models [33,34].
Another distinctive feature is that the dystrophin-deficient cardiac muscle of our
DMDex52del pig model showed the disrupted expression levels of DAPs but no obvious
histopathological abnormalities. Since cardiomyopathy due to the absence of dystrophin
is more manifested with advancing age in patients [53] and canine models [55,56], pig
models may also display histological and functional abnormalities in the heart later dur-
ing life. Detailed cardiac assessment of the DMD pigs will be a challenge due to their
shorter lifespan.
A report of similar severity in another cloned porcine DMD model with the same
exon 52-deletion but a different genetic background also substantiates the value of the
tailored DMDex52del pig model as a severe dystrophic model for a better understanding of
DMD pathology [28]. Interestingly, consistent with our results, their DMDex52del pigs have
exhibited severe degeneration in skeletal but not in cardiac muscle. They also manifested a
reduced growth rate as seen in the present study, surviving only up to 3 months of age;
shorter than the 7 months we noted with our DMDex52del. A DMD miniature pig model
with a Chinese Diannan breed has also been reported with the CRISPR/Cas9 system used
for DMD exon 27-targeting-knockout, showing a short lifespan of 52 days [29]. In the
present study, 5 out of 7 affected male piglets died or were euthanized within a week.
Such early neonatal death is reported as a fulminant neonatal form in some puppies of the
GRMD dog model [36], though the pathogenic mechanism remains unclear. Associated
with the fulminant case, it also needs to be investigated how epigenetic dysregulation
in genetically modified pig cells influences phenotypic instability [57,58]. The severe
pathology observed in the porcine models reported so far may provide insight into the
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mechanism of progressive dystrophic changes in skeletal muscles. In addition, phenotypic
variation between strains or littermates of DMD pigs needs to be characterized for pig
models to be used in the preclinical field.
While the progressive and severe signs in DMDex52del pigs partially resemble DMD
patients, the rapidity and severity of their disease may raise a concern when distributing
them as a tool for translational research; i.e., it could mask the therapeutic effects of drugs
tested. To overcome such a limitation, Nagashima’s group, using chimeric embryos of
normal and genetically modified blastomeres prepared by SCNT, has previously reported
generating a DMDex52del pig model showing a milder dystrophic phenotype [30]. Given the
severity of the cloned models, the establishment and maintenance of the generated mutant
strains represent a significant challenge in developing the DMD pig model. As described
previously, male DMD pigs, including our model, did not reach the age or keep the health
condition to allow for breeding, indicating that affected piglets need to be prepared by
SCNT when one needs them. Efforts to generate a carrier of female pigs with heterozygous
DMD mutation in an X-chromosome allele (DMD+/−) have been made with genome editing
of germinal oocytes [59]. Encouragingly, Wang and Lei’s group and Kupatt’s group have
reported heterozygous female DMD+/− pigs that enable the production of affected male
DMDY/− offspring [31,60]. We also succeeded in generating female miniature pig-derived
fibroblast cell lines that harbour the DMD+/− genotype composed of wild-type and exon
52-deleted alleles (data not shown), paving the way to generate the carrier miniature sow
through SCNT as we previously demonstrated for a pig model of another genetic disease,
cystic fibrosis [48]. As there is limited information regarding the phenotype of DMD
carrier female pigs and non-cloned DMDex52del male offspring, further characterization is
needed to compare the phenotype of non-cloned DMDex52del male offspring with clonal
male founders produced using SCNT.
An advantage of the exon 52 deletion we created in pigs is that this mutation theoreti-
cally allows for evaluating exon 51 and exon 53 skipping to treat the highest proportion
(19.6% and 15.3%, respectively) of patients having DMD out-of-frame deletion muta-
tions [27]. For the same reason, a dystrophic mouse model with mouse Dmd exon 52
deletion, called an mdx52 mouse, was generated [61]. The mdx52 mice significantly con-
tributed to establishing the proof-of-concept of exon 51 and 53 skipping therapies for which
PMO-based ASO drugs have become commercially available [4,62]. While mouse models
act as a hub for DMD research, DMDex52del pigs, being closer to patients in terms of many
physical traits, are expected to become a practical approach to bridge the gap between
pre-clinical and clinical results. Here, we confirmed that the exon 52-deleted DMD gene is
amenable to both PMO-meditated exon 51 and 53 skipping in vitro, correcting the reading
frame in DMDex52del pig-derived skeletal muscle cells. Thus, we demonstrated that the
primary skeletal muscle cells of DMDex52del pigs serve as a valuable tool for sensitive ASO
screening before the validation using live animals. Towards in vivo testing, unanticipated
splicing events involving exon(s) other than a target exon need to be investigated to make
the exon-skipping results in the model more reliable.
Another important finding is that the ASO predictive tool that we have developed for
human DMD [38] can be used to discover effective pig PMO sequences. Interestingly, the
profiles of predicted skip efficacy across pig exons 51 and 53 resembled those of humans.
The robustness of the pig ASO prediction was validated with the empirical assay of exon
skipping in the primary DMDex52del pig skeletal muscle cells. In the proof-of-concept
stage, a time-consuming in vitro screening using animal cells is needed to identify ASOs
to be used for in vivo testing in animal models. Our ASO predictive tool can help to find
effective ASO sequences to skip exon(s) of interest by narrowing down the candidate
ASOs from among the hundreds of potential target sites on a given exon [63], as shown in
Tables S4 and S5. Although current procedures are effective, there is a need to improve
the accuracy of predictive algorithms as more data become available on different lengths,
chemistries, and sequence-specific safety of ASOs. An effective in silico tool can reduce
the time spent finding effective ASOs and accelerate the pre-clinical process when used
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in combination with an appropriate animal and its cell models such as DMDex52del pigs.
Indeed, our combination method using in silico and in vitro screening identified candidate
PMO sequences, particularly pEx51_Ac48 and pEx53_Ac26 sequences, to be used for
in vivo testing in the DMD pigs.
The PMO chemistry is one of the optimal chemistries for clinical application for
exon skipping, as evidenced by the recent regulatory approvals [4]; however, its limited
efficacy has been raised as a challenge requiring improvement [40]. The conjugation of
a CPP to PMOs has attracted attention as a solution because it increases exon skipping
efficacy in both patient cells and animal models [15]. We have previously demonstrated the
increased potency of CPP-conjugated PMOs in skeletal and cardiac muscles of the CXMDJ
dog model [21]. Currently, various CPPs including the P7-peptide used here have been
developed and tested, aiming at clinical use, which requires evaluations of efficacy and
safety using appropriate in vitro and in vivo models. Indeed, an immortalized CXMDJ
skeletal muscle cell model was recently developed for PPMO screening [43]. The present
study also demonstrated that the DMDex52del pig-derived skeletal muscle cells allow for
the evaluation of PPMO efficacy in vitro; the P7 conjugation potentiates by up to 40-fold
the ability of a given concentration of PMO to skip pig DMD exon 51 or 53 than is the case
without the conjugation, as shown in Figure 7. This result is encouraging for in vivo testing
of the PPMO-mediated exon skipping approach in DMDex52del pigs.
In conclusion, using a combination method of rAAV-mediated gene targeting and
SCNT [24], we developed a tailored DMD mutant miniature pig model with an exon 52
deletion mutation frequently seen in patients. Consequently, we successfully produced
clonal DMDex52del pigs that display progressive and severe signs accompanied by a lack
of dystrophin protein and disruption of DAPs’ assembly in body-wide skeletal and heart
muscles. Through in vitro testing using the primary DMDex52del pig skeletal muscle cells,
our findings indicate the potential for DMDex52del pigs to serve as an in vivo tool for
evaluating the efficacy and safety of exon skipping induced by ASOs, and in particular,
the more recently developed CPP-conjugated PMOs. Although there are technical and
financial challenges in developing large animal models, generating various pig models
with DMD mutations of interest and establishing a steady offspring supply could provide
an effective tool to help the development of therapies for DMD patients.
4. Materials and Methods
4.1. Animals
All animals used in the present study were developed and housed in the Public
Health Service (PHS)-assured facilities of Exemplar Genetics (Sioux Center, IA, USA).
Standards and recommendations outlined in the Guide for the Care and Use of Laboratory
Animals (NRC, 2011) and the PHS Policy were applied to husbandry and animal care.
The Institutional Animal Care and Use Committee of Exemplar Genetics approved all
animal experiments. Exemplar Genetics is also AAALAC accredited. The pigs were
euthanized by i.v. injection of pentobarbital sodium (150 mg/kg; Intervet/Merck Animal
Health, Kenilworth, NJ, USA) [64] following American Veterinary Medical Association
guidelines. Subsequently, skeletal and cardiac muscles were collected for histological and
molecular analyses.
4.2. Fetal Fibroblasts
Porcine fetal fibroblasts were prepared from male Yucatan miniature pig fetuses at
day 35 as previously described [24,65]. Briefly, fibroblasts were cultured at 39 ◦C in F10
media (Invitrogen, Carlsbad, CA, USA), containing 20% FCS and 30 µg/mL gentamicin.
The sex of the fetuses was determined by PCR for the Y chromosome-specific Sry gene [66].
4.3. Targeting Vector Construction
The pig DMD targeting vector was essentially constructed according to previous stud-
ies [24,67]. Genomic DNA was extracted from the fetal fibroblasts prepared above (Qiagen,
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Germantown, MD, USA). A DNA region including DMD exon 52 and flanking introns was
amplified using a high fidelity polymerase (Platinum Taq High Fidelity, Invitrogen). The
PCR product was sub-cloned into pCR2.1-TOPO (Invitrogen) and sequenced. The resulting
plasmid was used as a template for PCR amplification of the 5′ and 3′ homologous targeting
arms sub-cloned sequentially into a plasmid containing a cassette of the phosphoglycerate
kinase promoter and neomycin resistance cDNA. The construct was designed to replace
the endogenous DMD exon 52 with the cassette (Figure 1B).
4.4. rAAV Vector Production
The targeting vector sequence with a 4.5 kb amplicon size described above was sub-
cloned into the rAAV2 pro-viral plasmid, pFBAAV2-CMVP.NpA (obtained from University
of Iowa Viral Vector Core Facility, Iowa City, IA, USA) and grown in Sure2 competent cells
(Stratagene, La Jolla, CA, USA), as previously described [24]. The rAAV was produced
with the help of the University of Iowa Viral Vector Core Facility.
4.5. Generation of DMD Exon 52-Taregetted Pig Fibroblasts
Male fetal fibroblasts were treated with the rAAV vector prepared above to remove
DMD exon 52 from the pig genome via homologous recombination as previously de-
scribed [24]. In brief, 24 h after seeding the primary fibroblasts (1.5 × 106) that were
cultured without passaging, the cells were infected with the rAAV having the DMD tar-
geting construct. Twenty-four hours after the infection, the cells were trypsinized and
transferred to 96-well collagen-coated plates (BD Biosciences, San Jose, CA, USA). In 48 h,
G418 (100 µg/mL) was added to the individual wells to select the targeted cells. Ten days
later, each well was trypsinized (60 µL trypsin, 0.5% EDTA) for the cell collection. DMD
exon 52 deletion and replacement by the NeoR was confirmed through PCR screen and
direct-sequencing.
4.6. Somatic Cell Nuclear Transfer and Embryo Transfer
To produce the affected male piglets, SCNT and embryo transfer to recipient gilts
were performed by Trans Ova Genetics (Sioux Center, IA, USA) and Exemplar Genetics as
previously described [24,68]. Briefly, metaphase II chromosomes and the polar body were
aspirated from oocytes by a micropipette, and then the donor fibroblast was deposited into
the enucleated oocytes. Following the fusion and activation, the reconstructed oocytes were
transferred into synchronized postpubertal domestic gilts on the first day of standing estrus
under general anesthesia with i.v. propofol (0.5–5 mg/kg) and the inhaled isoflurane (3–5%
in oxygen via face mask). Recipient animals were checked for pregnancy by abdominal
ultrasound after day 21 and throughout a 114 day gestation period.
4.7. Genotyping Assay and Southern Blotting
Cloned piglets were genotyped to confirm the mutation with DMD exon 52 deletion
by PCR (Figure 2A). The deletion mutation in the genomic DNA was further validated by
Southern blotting using a probe that detects the pig DMD downstream of the targeting
boundary or NeoR sequence (Figure 2B) as previously described [24].
4.8. Creatine Kinase Levels
Blood samples were collected from pigs within 24 h after birth to test serum creatine
kinase levels [69]. Samples were submitted to a commercial laboratory (Marshfield Labs)
for the measurement.
4.9. Tissue Samples
Skeletal and cardiac muscle blocks from wild-type and affected pigs were prepared as
previously described [70]. Muscle samples were obtained immediately after the euthanasia
and snap-frozen in liquid nitrogen-cooled isopentane. The samples were stored at −80 ◦C
before use.
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4.10. Histological Analyses
Skeletal and cardiac muscles were sectioned at 7–10 µm for histological analyses.
H&E staining was conducted as previously described [35]. Masson’s trichrome staining
was performed according to the TREAT-NMD SOP MDC1A_M.1.2.003. For immunohis-
tochemistry with serial sections of muscle tissues, the unfixed sections were incubated
with antibodies listed in Table S1. The signals visualized through fluorescence-conjugated
secondary IgG antibodies were evaluated at 200× magnification using a Nikon Eclipse
TE2000-U microscope (Nikon, Mississauga, ON, Canada), as previously described [52].
4.11. RT-PCR
Total RNA from frozen tissue sections or cultured cells was extracted with TRIzol
reagent (Invitrogen) [21,39]. RT-PCR was performed in a 25-µL mixture containing 280 ng
RNA using the SuperScript III One-Step RT-PCR System with Platinum Taq DNA Poly-
merase (Invitrogen) and primers (Table S2) following the manufacturer’s instructions. The
cycling conditions are as follows: 50 ◦C for 10 min; 94 ◦C for 2 min; 35–40 cycles at 94 ◦C
for 15 s, 60 ◦C for 30 s, and 68 ◦C for 30 s; and 68 ◦C for 5 min. PCR products were elec-
trophoresed on a 1.5% agarose gel and visualized by SYBR Safe DNA Gel Stain (Invitrogen).
The images were pictured in the KODAK Image Station 4000 MM (Kodak, Rochester, NY,
USA) or the ChemiDoc Touch imaging system (Bio-Rad, Mississauga, ON, Canada).
4.12. Western Blotting
Protein extraction from frozen muscle sections or cultured cells was performed as
previously described [52,63]. In brief, 30–50 µg of protein of the muscle sections or cells were
loaded onto a NuPAGE Novex 3–8% Tris-Acetate or 4–12% Bis-Tris Midi Gel (Invitrogen)
and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis at 150 V for
75 min. The proteins were transferred onto an Immobilon PVDF membrane (Millipore)
by semidry blotting at 20 V of constant voltage for 70 min. The membrane was blocked
with phosphate-buffered saline containing 0.05% Tween 20, 0.1% casein and 0.1% gelatin,
or 3% ECL blocking agent (GE Healthcare, Mississauga, ON, Canada). Blots were reacted
with primary antibodies listed in Table S3 at 4 ◦C overnight, followed by the incubation
with horseradish peroxidase-conjugated secondary IgG antibodies appropriate to react
with the primary antibodies. Following the incubation with a chemiluminescent reagent
(ECL Select, GE Healthcare), images of the blots were captured in the KODAK Image
Station 4000 MM or the ChemiDoc Touch imaging system. Myosin heavy chain (MyHC)
stained by Coomassie Brilliant Blue in post-transferred gels served as a loading control for
individual muscle samples. In cell experiments, because of heterogeneous populations of
primary cells, i.e., varying proportions of myogenic cells between individual primary pig
cells established, primary healthy pig skeletal muscle cells were used as a qualitative index.
4.13. Design and Synthesis of Antisense Oligonucleotides
All possible ASO sequences 30-mer in length were considered for skipping exon 51 or
53 in the pig DMD gene (Tables S4 and S5, respectively). Exon skipping efficiencies of the
designed ASO sequences were quantitatively predicted using the previously developed
computational tool (Figure S1) [38]. The predicted values were evaluated to select ASOs
to be used for the empirical test. ASO sequences experimentally tested were synthesized
with the PMO chemistry by Gene Tools. PMOs with Ac48 and Ac26 to skip pig DMD
exon 51 and 53, respectively, were conjugated with P7-peptide by H.M.M. (Oregon State
University) [44].
4.14. Primary Skeletal Muscle Cells of DMD Pigs
Skeletal muscle tissues from two wild-types (IDs 14425 and 14426) or transgenic DMD
pigs (IDs 9584 and 9585) were washed and collected in a sterilized PBS(-) immediately
after euthanizing them. Ten grams of skeletal muscles, of which the damaged areas and
connective tissues were trimmed, were minced with sterilized forceps. Tissues were
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digested with 20 mL of 0.2% Collagenase Type 2 (Worthington, Columbus, OH, USA, cat#
CLS-2) in Hanks’ Balanced Salt Solution(-) for 45 min at 37 ◦C mixing with a spin bar.
Then the supernatant was collected in the equivalent amount of cooled DMEM/F12 (Gibco,
Grand Island, NY, USA, cat# 11330-057) with 10% fetal bovine serum, 0.5% penicillin and
streptomycin (Gibco, cat# 15140-122), and 50 µg/mL gentamicin. The process was repeated
twice using the fresh digestive agent. Following the filtration with 100 and 40 µm cell
strainers and centrifugation at 400× g for 5 min, cells were resuspended with growth media:
DMEM/F12 containing 20% FBS, supplement mix (Promocell, Heidelberg, Germany, cat# C-
39365), 0.5% penicillin and streptomycin, and 50 µg/mL gentamicin. The cells were seeded
to regular plastic flasks for the pre-plating to remove fibroblasts from the cell population
for 1–2 h. The supernatant containing floating cells was transferred into flasks coated
with 0.4% gelatin derived from porcine skin (Sigma-Aldrich, St. Louis, MO, USA, cat#
G2500). The primary skeletal muscle cells were passaged three to five times in the growth
media, and the batches of the cells were frozen and stored for subsequent experiments to
minimize the effect of the heterogeneous cell population between cell batches. Cells were
differentiated to myotubes with DMEM/F12 with 2% horse serum heat-inactivated, 1× ITS
(Sigma-Aldrich, cat# I3146-5ML), and 0.5% penicillin and streptomycin.
4.15. In Vitro PMO Transfection
ASO transfection was performed as previously described [39] with modifications for
the primary pig skeletal muscle cells, as shown in Figure S2A,B. In brief, the cells at the
density of 2.6× 104/cm2 were seeded in collagen type I-coated culture plates, then cultured
in the growth media described above. On day 2 after the seeding, the cells at the density of
>95% were differentiated to myotubes using the differentiation media. In 3 days after the
differentiation, the spent media were replaced with fresh ones containing unmodified or
P7-conjugated PMOs. In 2 or 1 day, the PMOs were removed. Following the culture of 4 or
2 days, the cells were collected for subsequent experiments with mRNA and protein [39].
4.16. Exon Skipping Efficiency
The feasibility of exon skipping in DMD pig skeletal muscle cells was tested using
PMOs or P7-PMOs with select ASO sequences [63]. RT-PCR was performed as described
above. Skipping percentage from the band intensity non-saturated was quantified by
ImageJ software (NIH) as follows: exon-skipping efficiency (%) = exons skipped transcript
intensity/(native + exon skipped transcript intensity) × 100. Bands of the expected size
for the exon-skipped transcript were extracted using a gel extraction kit (Promega). The
direct sequencing of the skipped bands was performed with Big Dye Terminator v3.1
(Applied Biosystems).
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